QURE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against UniQure N.V. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [2][4]. Group 1: Allegations Against UniQure - The complaint alleges that UniQure and its executives made false and misleading statements regarding the FDA approval of their Pivotal Study, which was not fully approved [4]. - It is claimed that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies, despite previously reported successful results [4]. - As a result of these actions, the statements made by the defendants about the company's business and prospects lacked a reasonable basis [4]. Group 2: Impact of FDA Disclosure - On November 3, 2025, UniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would support a BLA submission, leading to uncertainty about the timing of any submission [5]. - Following this disclosure, UniQure's share price fell by $33.40, or over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [6]. Group 3: Legal Proceedings - Investors who purchased UniQure securities between September 24, 2025, and October 31, 2025, are reminded of the April 13, 2026, deadline to seek the role of lead plaintiff in the federal securities class action against the company [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 4: Call for Information - Faruqi & Faruqi encourages anyone with information regarding UniQure's conduct, including whistleblowers and former employees, to contact the firm [8].